SAN DIEGO (dpa-AFX) - Boehringer Ingelheim Pharmaceuticals, Inc. and Qualcomm Inc. (QCOM) through its subsidiary, Qualcomm Life, Inc., announced a new collaboration to develop a connectivity solution for the RESPIMAT inhaler, the platform inhaler for the Boehringer Ingelheim family of respiratory therapies, to help improve COPD treatment outcomes.
The collaboration will be announced at Qualcomm Life's fifth annual Connect 2016 ecosystem conference, taking place on August 30 and August 31, 2016 in San Diego, California.
Through its 2net Design platform, Qualcomm Life is developing the prototype for a small, wireless, low-power, disposable module for the RESPIMAT inhaler. This fully-integrated inhaler, which is designed to seamlessly connect with Qualcomm Life's 2net Platform, will be able to track puffs from the RESPIMAT inhaler, and the collected information can be shared with health care providers and people who have been prescribed one of Boehringer Ingelheim's RESPIMAT medicines.
Copyright RTT News/dpa-AFX